Genematrix

Genematrix Diluted EPS

The Diluted Earnings per Share of Genematrix (109820.KQ) as of Nov 13, 2026 is -114.41 KRW. In the previous year, Diluted Earnings per Share was -233.76 KRW — a change of -51.06% (higher).

Diluted EPS

-114.41KRW

YoY

-51.06%

Last updated:

Diluted Earnings per Share of Genematrix is 2025 -114.41 KRW. Diluted Earnings per Share of Genematrix was 2024 -233.76 KRW. It decreases by -51.06% higher compared to the previous year.

The Genematrix Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-193.75 KRW
Jan 1, 2019
-85.23 KRW
Jan 1, 2020
500.80 KRW
Jan 1, 2021
-61.60 KRW
Jan 1, 2022
-505.88 KRW
Jan 1, 2023
-55.81 KRW
Jan 1, 2024
-233.76 KRW
Jan 1, 2025
-114.41 KRW
The Genematrix Diluted EPS history
YEARDiluted EPSYoY
-114.41KRW-51.06%
-233.76KRW+318.81%
-55.81KRW-88.97%
-505.88KRW+721.25%
-61.60KRW-112.30%
500.80KRW-687.61%
-85.23KRW-56.01%
-193.75KRW+102.00%
-95.92KRW-59.28%
-235.56KRW+86.97%
-125.99KRW+79.91%
-70.03KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genematrix Stock analysis

What does Genematrix do? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genematrix stock

Diluted Earnings per Share of Genematrix is -114.41 KRW in 2025.

Diluted Earnings per Share of Genematrix changed from -233.76 KRW to -114.41 KRW, representing a -51.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Genematrix since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genematrix

All Key Metrics — Genematrix